Powder: -20°C for 3 years | In solvent: -80°C for 1 year
GDC-0879 (AR-00341677) 是一种选择性B-Raf 抑制剂,IC50为 0.13 nM。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 282 | 现货 | ||
2 mg | ¥ 395 | 现货 | ||
5 mg | ¥ 638 | 现货 | ||
10 mg | ¥ 996 | 现货 | ||
25 mg | ¥ 1,970 | 现货 | ||
50 mg | ¥ 3,180 | 现货 | ||
100 mg | ¥ 4,620 | 现货 | ||
200 mg | ¥ 6,490 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 698 | 现货 |
产品描述 | GDC-0879 (AR-00341677) is a novel, potent and selective B-Raf inhibitor with IC50 of 0.13 nM with activity against c-Raf as well. |
靶点活性 | B-Raf:0.13 nM |
体外活性 | GDC-0879 also inhibits cellular pERK with IC50 of 63 nM. GDC-0879 shows comparable potency in A375 melanoma and Colo205 colorectal carcinoma cell lines, both of which are B-RafV600E mutant, with IC50 of 59 nM and 29 nM for pMEK1 inhibition respectively. GDC-0879 potently inhibits B-RafV600E in Malme3M cells with IC50 of 0.75 μM. GDC-0879 also shows EC50 values < 0.5 μM in many tumor cells (A375, 624, SK-MEL-28, Malme3M, C32, 928, 888, G-361, Colo205, Colo206, SW1417, CL34, and Colo201). [1] |
体内活性 | In GDC-0879 treated mice, both cell line- and patient-derived BRAFV600E tumors exhibit stronger and more sustained pharmacodynamic inhibition (>90% for 8 hours) and improved survival compared to mutant KRAS-expressing tumors. Although there is involvement of activated RAF signaling in RAS-induced tumorigenesis, decreased time to progression is observed for some KRAS-mutant tumors following GDC-0879 administration. Whereas GDC-0879-mediated efficacy is associated strictly with B-RafV600E status, MEK inhibition also attenuates proliferation and tumor growth of cell lines expressing wild-type BRAF (81% KRAS mutant, 38% KRAS wild type). The responsiveness of B-RafV600E melanoma cells to GDC-0879 could be dramatically altered by pharmacologic and genetic modulation of PI3K pathway activity. [2] |
别名 | GDC 0879, AR-00341677, GDC0879 |
分子量 | 334.37 |
分子式 | C19H18N4O2 |
CAS No. | 905281-76-7 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 33.4 mg/mL (100 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.9907 mL | 14.9535 mL | 29.907 mL | 74.7675 mL |
5 mM | 0.5981 mL | 2.9907 mL | 5.9814 mL | 14.9535 mL | |
10 mM | 0.2991 mL | 1.4953 mL | 2.9907 mL | 7.4767 mL | |
20 mM | 0.1495 mL | 0.7477 mL | 1.4953 mL | 3.7384 mL | |
50 mM | 0.0598 mL | 0.2991 mL | 0.5981 mL | 1.4953 mL | |
100 mM | 0.0299 mL | 0.1495 mL | 0.2991 mL | 0.7477 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
GDC-0879 905281-76-7 MAPK Raf Inhibitor GDC 0879 Raf kinases AR00341677 AR 00341677 AR-00341677 GDC0879 inhibit inhibitor